Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
8 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Regeneron and Sanofi have expanded their antibody alliance to co-develop four long-acting immunology antibodies. Regeneron will receive a $1 billion upfront payment and up to $7 billion in potential milestones, with costs and profits to be shared 50:50 globally.
Sanofi and Regeneron Pharmaceuticals have expanded their long-standing antibody collaboration, adding multiple next-generation, long-acting immunology antibodies to their pipeline.
REGN20423 In Phase 1; Three More Antibodies Expected To Enter Studies In 2027 - Alliance May Include Sanofi s Lunsekimig Following Phase 3 Studies - Companies Settle Previous Collaboration-Related Litigation
Regeneron Pharmaceuticals (REGN) has expanded its antibody collaboration with Sanofi, adding four long-acting immunology antibodies. Regeneron will receive $1 billion upfront and could receive up to $7 billion in milestones. The companies will share costs and split future profits 50:50 globally.
Regeneron and Sanofi are expanding their global alliance with the addition of REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody, and two other preclinical long-acting antibodies. Regeneron will receive $1 billion upfront with potential for future payments.
Regeneron and Sanofi said they are expanding their global alliance with multiple next-generation, long-acting immunology antibodies.
Sanofi (NASDAQ: SNY ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Sanofi delivered a stro
On Monday, AstraZeneca (NASDAQ: AZN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary AstraZeneca reported a 6% growth in total revenue for the fi